Pharming Group N.V. (PHAR) delivered a return of 15.79% over the past year. Since PHAR does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Pharming Group N.V. one year ago would be worth $11,579 today, representing a gain of $1,579.

Pharming Group N.V. (PHAR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For PHAR, the total return equals the price-only return.

No, Pharming Group N.V. (PHAR) underperformed the S&P 500 by 5.05 percentage points over the past year. PHAR delivered a total return of 15.79%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed PHAR by 5.05pp during this period.

Pharming Group N.V. (PHAR) experienced a maximum drawdown of -43.34% over the past year, declining from its peak on 2026-01-27 to its trough on 2026-05-07. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Pharming Group N.V. (PHAR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -22.3% (-2.5% CAGR) — $10,000 would have grown to $7,772. Over 20 years: -22.3% total return (-1.3% CAGR) — $10,000 → $7,772. Over 30 years: -22.3% total return (-0.8% CAGR) — $10,000 → $7,772. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Pharming Group N.V.'s best calendar year was 2025 with a total return of 68.9%. Its worst year was 2021 with a total return of -40.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 109.0 percentage points.